X-Message-Number: 12070 From: Date: Mon, 05 Jul 1999 10:20:50 -0700 Subject: Announcement from BioTransport, Inc, CryoCare Foundation, and Advanced BioSciences, Inc. References: <> July 1, 1999 As of July 1st, 1999, principals of BioTransport, Inc., CryoCare Foundation, and Advanced BioSciences, Inc. have signed a binding letter of intent affirming that Advanced BioSciences intends to sublicense new cryopreservation technology to BioTransport, and BioTransport intends to use this technology to provide enhanced service to Alcor and CryoCare members. While a formal contract has not been negotiated, principals at the three companies are optimistic that such a contract can exist by the end of this year. BioTransport was formed initially by Fred Chamberlain, Linda Chamberlain, Joe Hovey, and Michael Riskin, of Alcor, as an independent provider of human cryopreservation services including remote standby, transport, perfusion, and cooldown. Michael Riskin, who is now CFO and Vice President of BioTransport, has taken a highly active role this year in developing the new company as an independent provider of human cryopreservation services including remote standby, transport, perfusion, and cooldown. It will first offer its services to CryoCare and Alcor members, with others to follow if satisfactory contracts can be negotiated. Advanced BioSciences was created this year to develop cryonics applications from recent research at 21st Century Medicine. 21st now conducts only cryobiology research, having spun off its hypothermia and resuscitation projects into a new, separate company named Critical Care Research. 21st has no involvement in cryonics and will be launching sales of its first product this summer, the SuperCool X-1000 Ice Blocker. CryoCare Foundation and the Alcor Foundation are cryonics organizations whose needs are complementary. Alcor has expressed interest in results of recent research, while CryoCare wishes to restore its ability to deliver remote- standby service and enhance its cryopreservation services. BioTransport should be able to satisfy these needs on a basis that will be mutually beneficial. In the future, BioTransport and/or Advanced BioSciences may negotiate agreements with additional clients. Currently, however, Alcor and CryoCare are the only cryonics organizations negotiating to receive improved technology from Advanced BioSciences and cryopreservation service from BioTransport. This announcement is made jointly by Saul Kent, Chairman and CEO of Advanced BioSciences and 21st Century Medicine; Charles Platt, President of CryoCare; and Michael Riskin, CFO and Vice President for Business Development at BioTransport. ------------------------------------------------------------- Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=12070